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Abstract
Nutrigenomics is a relatively new branch of nutrition science, which aim is to study the impact of the foods we eat on 
the function of our genes. Hepatosteatosis is strongly associated with hepatitis C virus infection, which is known to 
increase the risk of the disease progression and reduce the likelihood of responding to anti- virus treatment. It is well 
documented that hepatitis C virus can directly alter host cell lipid metabolism through nuclear transcription factors. To 
date, only a limited number of studies have been on the effect of human foods on the nuclear transcription factors of 
hepatitis C virus -induced hepatosteatosis.
Three nutrients, selected among 46 different nutrients: β-carotene, vitamin D2, and linoleic acid were found in a cell 
culture system to inhibit hepatitis C virus RNA replication. In addition, polyunsaturated fatty acids (PUFAs) especially 
arachidonic acid (AA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) have been demonstrated to 
inhibit hepatitis C virus RNA replication. These PUFAs, in particular the highly unsaturated n-3 fatty acids change the 
gene expression of PPARa and SREBP, suppress the expression of mRNAs encoding key metabolic enzymes and hereby 
suppress hepatic lipogenesis and triglyceride synthesis, as well as secretion and accumulation in tissues. A recent 
prospective clinical trial of 1,084 chronic hepatitis C patients compared to 2,326 healthy subjects suggests that chronic 
hepatitis C patients may benefit from strict dietary instructions.
Increasing evidence suggest that some crucial nuclear transcription factors related to hepatitis C virus -associated 
hepatosteatosis and hepatitis C virus RNA itself can be controlled by specific anti- hepatitis C virus nutrition. It seems 
important that these findings are taken into account and specific nutritional supplements developed to be used in 
combination with interferon as adjunctive therapy with the aim to improve both the early as well as the sustained 
virological response.
Introduction
The term nutrigenomics was coined in 1999 by Nancy
Fogg-Johnson and her colleague Alex Meroli. The aim of
nutrigenomics is to study how various diet ingredients
affect the expression of specific genes and hereby provide
tools to understand and control the worldwide epidemic
of specific chronic diseases, particularly obesity, cancer,
cardiovascular disease, diabetes and neurodegenerative
diseases such as Alzheimer and Parkinson's disease.
These diseases often arise from dysfunctional biological
networks, and no single common gene mutation seems
responsible, i.e. they appear as polygenic diseases[1-3].
The principle that one gene leads to one protein or one
metabolite has in recent years proved to be too simplistic
and often incorrect, as demonstrated in experimental
studies. Consequently, the traditional "one drug one tar-
get" paradigm may not be an effective or the most effec-
tive for a successful treatment of polygenic, diet-related
diseases. Indeed, the diet, comprised of a multitude of
nutritional and chemical molecules, capable of interact-
ing and regulating gene expression and influencing dispa-
rate biological processes, has the potential to profoundly
influence the Society: disease pattern and health econ-
omy. "We are what we eat".
Performing population-scaled epidemiological studies
in the absence of genetic knowledge may result in errone-
ously scientific conclusions and misleading nutritional
recommendations. Nutrition research has shifted from
epidemiology and physiology to molecular biology and
genetics. Nutrition can no longer be viewed as simply
epidemiological studies, which aims are to identify rela-
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ically uncharacterized populations. Instead
nutrigenomics provide tools to look at a deeper level and
study the effect of nutrition on molecular and genetic lev-
els and develop/produce diets with the potential to pre-
vent or at least retard the spreading of serious and today
widespread chronic diseases including Alzheimer, cancer,
and type 2 diabetes. Nutrigenomics offers an exciting
area that profoundly will change future direction of not
only nutrition, but medicine as a whole, and most likely
also Society.
Hepatosteatosis is strongly associated with HCV infec-
tion. Recent studies suggest a tight link between HCV
infection and hepatic cell lipid metabolism. Several can-
didate transcription factors with capacity to mediate
cross-talks between HCV RNA replication and lipid
metabolism have been identified. Since the original
observation more than a decade ago that dietary fats act
as regulators of gene expression, many transcription fac-
tors and prospective targets for fatty acid regulation have
been identified. However, so far only a limited number of
studies have reported the influence of dietary sources of
nutrients on hepatitis C virus (HCV) RNA- induced
hepatosteatosis[4]. A recent clinical study comparing
1,084 patients with biopsy-proven HCV-related chronic
hepatitis (432 treated with interferon plus ribavirin) with
2,326 healthy subjects, reports a strong association
between the composition of diet and severity of HCV-
related chronic hepatitis [5] and some dietary compo-
nents were associated with nonresponse to antiviral ther-
apy. This suggests that HCV patients may benefit from
instructions regarding their diet.
The focus of this discussion is the mechanisms of
dietary control of gene expression in HCV-induced ste-
atosis, and the aim is to provide practical applications of
nutrigenomics, advocating that chronic hepatitis C
patients should also receive anti-HCV nutrients as an
adjunctive therapy in combination with anti-virus drugs.
The Link Between HCV Core Protein and Genes 
Involved in Lipid Metabolism
Although it seems that all genotypes can trigger steatosis,
the risk of developing steatosis is significantly higher for
people with genotype 3. There is a complex reaction
between the genotype 3 virus and liver cells, not seen in
other genotypes, giving this group a much higher risk to
develop severe steatosis. Around 40% of individuals with
hepatitis C have steatosis, compared to between 14% and
31% of the general population. In sharp contrast to this,
60% - 80% of individuals with genotype 3 present with
moderate or severe steatosis [6,7].
HCV is an enveloped virus belonging to the Flaviviridae
family. The viral genome is a linear, positive-stranded
RNA molecule of 9600 nucleotides, that contains a single
open reading frame which codes for a polyprotein of 3000
amino acids. The amino-terminal portion of the viral
RNA encodes for the structural proteins (C, E1, and E2),
followed by the nonstructural proteins (NS2, NS3, NS4A,
NS4B, NS5A, and NS5B)[8].
Though the exact mechanism remains elusive, it seems
firmly established that hepatitis C virus itself can directly
alter host cell cholesterol/lipid metabolism through lipo-
genetic genes and thereby induce hepatic steatosis. Three
transcription genes MTP, PPAR-á and SREBP-1c may
involved in HCV interference with lipid metabolism and
at three levels: increased triglyceride synthesis, decreased
β-oxidation and decreased hepatic export of triglycerides
as VLDL.
Microsomal triglyceride transfer protein (MTP) is a
major regulator of the assembly and secretion of nascent
triglyceride -rich VLDL particles. Perlemuter et al.
[9]demonstrate that hepatic overexpression of HCV core
protein interferes with the hepatic assembly and secre-
tion of VLDL and inhibits microsomal triglyceride trans-
fer protein (MTP) activity [10]. In support of this
observation, some studies have reported a higher preva-
lence of hypocholesterolemia and hypobetalipoproteine-
mia in HCV-infected patients compared with control
groups [11,12]. Transgenic mice expressing the HCV full-
length polyprotein at low levels have decreased plasma
triglyceride levels and develop hepatocellular steatosis in
the same way as HCV-infected patients[13].
Another well known transcription factor that contrib-
utes to de novo fatty acid synthesis in the liver is SREBPs,
including three isoforms: SREBP-1a, SREBP-1c and
SREBP-2. Although, SREBP-1 and SREBP-2 are structur-
ally similar, their regulation in the liver by nutrients and
hormones is quite different. SREBP-1c controls the
hepatic and whole body cholesterol and fatty acid synthe-
sis. While SREBP-2 plays a major role in the regulation of
cholesterol synthesis and uptake, and the SREBP-1a
mainly regulate multiple facets of fatty acid synthesis and
VLDL assembly [14,15]. Individual HCV proteins,
regardless of HCV genotype, are reported to be able to
stimulate lipogenic genes through activation of all three
isoforms of SREBPs. Transcription of FAS and SREBP-1c
is most likely a main mechanism for HCV-mediated lipo-
genesis through LXR transcriptional activation. It is yet,
however, not fully understood how HCV induces activa-
tion of LXR and subsequently SREBP-1c [16].
PPARs are ligand-activated nuclear receptors belonging
to the steroid/thyroid hormone receptor superfamily; 3
isoforms designated as α, β/δ, and γ, all of them are
involved in lipid homeostasis [17]. PPARα regulates tar-
get genes encoding fatty acid-metabolizing enzymes,
known to be involved in fatty acid uptake, β-oxidation,
transport into peroxisomes, and ω-oxidation of unsatu-
rated fatty acids. Administration of PPARα agonists, such
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brozil, and fenofibrate, ameliorate hyperlipidemia in
humans and hepatic steatosis in mice [18-20]. However,
the association in humans between PPARα function and
chronic HCV infection remains a matter of controversy.
Rather paradoxical findings are obtained in the trans-
genic mice. Severe steatosis was unexpectedly observed
only in Ppara+/+:HCVcpTg mice with enhanced fatty acid
uptake and decreased mitochondrial β-oxidation due to
breakdown of mitochondrial outer membranes. Interest-
ingly, hepatocellular carcinoma developed in approxi-
mately 35% of 24-month-old Ppara+/+:HCVcpTg mice,
while tumors were not observed in Ppara+/-:HCVcpTg,
and Ppara-/-:HCVcpTg mice, suggesting that persistent
activation of PPARα is essential for the pathogenesis of
hepatic steatosis and HCC induced by HCV infections
[21].
HCV proteins associate with insulin resistant (IR). The
precise mechanisms whereby HCV induces IR remain
elusive, but recent progress has shed light on several crit-
ical pathways. Impairment of insulin receptor substrate -
1 and insulin receptor substrate -2 expressions have been
observed in the livers of HCV infected patients as well as
in HCV core transgenic mice. Specifically, HCV core pro-
tein has been shown to inhibit insulin induced phospho-
rylation of the p85 subunit of phosphatidylinositol 3-
kinase (PI3K) and Akt, which are downstream compo-
nents of insulin receptor substrate in the liver [22].
Dietary FFA Composition Inhibit HCV Replication 
and Hcv Induced- Lipogenesic Genes
Hepatic free fatty acids (FFAs) are de novo synthesized
within the hepatocytes, released by adipose tissue and
taken up by the liver, or generated in the liver by the
hydrolysis of chylomicrons from the intestine. The find-
ings indicate that changes in the fatty acid composition of
chylomicron remnants can alter the rate of their uptake
by the liver. It seems increasingly accepted that the fat
composition of diet not only constitute substrate for
energy metabolism, and are important for membrane for-
mation and expression of signaling molecules, but also
regulates gene expression[23], including hepatic fatty
acid-regulated transcription factors (PPARα, SREBP-1,
ChREBP and MLX). Since the steatosis and insulin resis-
tance are closely linked to the progression of liver disease
in HCV infected patients [24], such regulatory schemes
will impact whole body metabolism and contribute to
onset and progression of HCV infection, and more
importantly the facilitation of early virological response
(EVR) or a sustained viro-logical response (SVR).
Dietary fatty acid inhibit HCV RNA replication
This is partly due to the lack of suitable animal model, a
cell culture system (OR6 assay system) has been used to
study the efficient of HCV RNA replication, and shown to
be hampered by anti-HCV nutrients[25-28]. The study
examined comprehensively 46 different nutrients from
four nutrient groups: vitamins, amino acids, fatty acids,
and salts. Three nutrients--β-carotene, vitamin D2, and
linoleic acid were found to inhibit HCV RNA replication
and combination of the three caused additive and/or syn-
ergistic effects on HCV RNA replication. Furthermore,
combined treatment with each of the three nutrients and
interferon alpha or beta or fluvastatin inhibited in an
additive manner HCV RNA replication. In contrast, Vita-
min E was found to enhance HCV RNA replication and
negated the effects of the three anti-HCV nutrients and
cyclosporine, in contrast to those of interferon or fluvas-
tatin[29-32].
Also PUFAs have demonstrated the ability to inhibit
HCV RNA replication. It was observed in one study that
several PUFAs including arachidonic acid (AA), docosa-
hexaenoic acid (DHA), and eicosapentaenoic acid (EPA)
had the capacity to exert anti-HCV activities using an
HCV subgenomic RNA replicon system. PUFAs, such as,
arachidonic acid, EPA, and DHA, inhibited HCV RNA
replication already on the first day after initiation: arachi-
donic acid (≈4.5-fold (P = 0.0005), EPA (≈3-fold (P =
0.0047), and DHA (≈6.4-fold (P = 0.0002). In contrast,
saturated (lauric, myristic, and palmitic) and also mono-
unsaturated (oleic) fatty acids induced HCV RNA replica-
tion, observed as early as 4 days after initiation of
treatment. When AA was combined with IFN-α, strong
synergistic anti-HCV effect was observed as demon-
strated by an isobologram analysis [33,34]. Interestingly,
this study suggested that the PUFAs inhibit HCV RNA
replication by a mechanism independent of their ability
to inhibit lipogenic gene expression - by antagonizing
LXR-SREBP-1c Pathway.
The precise mechanism underlying the anti-HCV
activities of the nutrients are, however, not fully under-
stood and further studies needed to clarify the targets of
the nutrients responsible for their anti-HCV activities.
Dietary FFA composition affects HCV induced- Lipogenesic 
genes
Studies with various dietary fatty acids have revealed sev-
eral major metabolic pathways that are targeted by PUFA,
each pathway involving changes in gene expression [35-
37]. PPAR and SREBP-1c genes, known to induce fatty
acid oxidation and synthesis respectively are key targets
for PUFA control of hepatic gene expression. n-3 PUFAs
have rapid effects on gene expression, the changes in
mRNAs encoding several lipogenic enzymes can be
detected within hours of feeding animals diets enriched
in n-3 PUFA. Moreover, these effects are sustained as
long as the n-3 PUFAs remain in the diet. Two general
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expression:
1. Fatty acids bind directly to the transcription factor
and control transcription factor activities, such as
PPAR(α, β, γ1 & γ2), HNF-4 (α & γ), RXRα and LXRα. In
this fashion, fatty acids act like hydrophobic hormones
regulating the function of nuclear receptors and their
impact on transcriptional processes.
2. Fatty acids control the nuclear abundance of key
transcription factors, such as SREBP-1, NFκB, ChREBP
and MLX[38].
PPAR subtypes are the most widely accepted fatty acid-
regulated transcription factors. Certain fatty acids, how-
ever, are better than others at activating PPAR. Twenty-
carbon PUFA is an important determinant in the control
of PPAR activity and its target genes. PPARα binds 20:5n-
3, but not 18:1n9, and activates PPAR in rat primary
hepatocytes [39]. Activated PPAR induced- lipoprotein
lipase and fatty acid transporters (CD36) and enhance
adipocyte differentiation, inhibition of NFB function and
cytokine and expression of COX-2 [40,41]. The glita-
zones, e.g. troglitazone, pioglitazone, and rosiglitazone,
are pharmacological PPAR agonists and are used in the
treatment of insulin resistance. Pharmacological activa-
tion of PPAR and PPAR reduces lipid levels in muscle and
adipose tissue and improves insulin sensitivity in these
tissues [42,43]. Although n-3 PUFAs are weak agonists of
PPARs compared with pharmacological agonists, it has a
significant effect on insulin sensitivity in various tissues,
particularly skeletal muscle [44]. Thus, n-3 PUFA action
on insulin responsiveness in these tissues may extend
beyond its regulation of PPAR activity.
n-3 and n-6 PUFA are well-established suppressors of
mRNA SREBP-1 abundance, but not SREBP-2, through
inhibit SREBP-1 gene transcription, induce mRNASREBP-1
instability and inhibit SREBP processing. It has been
demostrated that 22:6, n-3, but not 20:4, n-6, is a major
regulator of nuclear SREBP-1 abundance and target
genes[45]. The ability of polyunsaturated fatty acids to
inhibit SREBP conversion from its inactive to its active
form relates to both physical and biochemical effects[46].
The physical mechanism is that addition of fatty acids to
these model membranes decreases the affinity of choles-
terol for phospholipid and this in turn results in
enhanced transfer from cholesterol-rich regions (such as
the plasma membrane) to cholesterol-poor regions (such
as the endoplasmic reticulum, leading to decreased
SREBP transport out of the endoplasmic reticulum to the
Golgi apparatus [47]. Another possible mechanism by
which polyunsaturated fatty acids decrease SREBP is by
changing the cellular composition of membranes. A
rather recent study showed that polyunsaturated fatty
acids increase the hydrolysis of plasma membrane sphin-
gomyelin to ceramide[48]. Lower amounts of sphingomy-
elin result in decreased ability to solubilize free
cholesterol, which leads to intracellular displacement of
cholesterol and a consequent decrease in SREBP-medi-
ated gene transcription[49]. Ceramide itself is through
effects on sphingolipid synthesis as a potent inhibitor of
SREBP processing [50], most likely contributing to regu-
lation of endoplasmic reticulum-Golgi vesicular trans-
port [51]. All this information supports the role and
interaction of polyunsaturated fatty acids in the different
steps of sphingolipid metabolism that affect SREBP pro-
cessing.
In vivo and vitro studies demonstrate that PUFAs have
the capacity to control hepatic gene expression and
hepatic lipid composition and hereby affect whole-body
lipid composition through regulating PPAR- and SREBP-
1c genes. However, more recent studies using a MCD
diet-fed model of steatohepatitis suggest that hepatic
lipid peroxidation correlate positively with the amount of
dietary PUFAs.
Because unsaturated fatty acids are excellent substrates
for lipid peroxidation, and because hepatic lipid peroxi-
dation is a prominent feature of MCD-related liver dis-
ease, unsaturated fat in the MCD formula are usually
regarded to play an important role in MCD-mediated
hepatotoxicity. The standard MCD formula contains 10%
corn oil, which is highly enriched in unsaturated fat. To
test the theory, MCD formulas with varying amounts of
unsaturated fat content from 2% to 59% were prepared
and their effects on steatosis, lipid peroxidation, and liver
injury were studied [52-55]. The results indicated that
hepatic lipid peroxidation is directly related to the
amount of unsaturated fat in the MCD diet, and that lipid
peroxidation correlates with hepatic induction of proin-
flammatory cytokine genes and hepatic inflammation.
Corn oil, the one of the most noxious fats was incorpo-
rated into the MCD formula, is rich in n-6 fatty acids.
High intake of n-6 fatty acids is known to be implicated in
the pathogenesis of nonalcoholic steatohepatitis in
humans. In contrast, n-3 fatty acids are reported to
improve nonalcoholic fatty liver disease.
A recent study addressed the role of n-3 fatty acids in
the MCD model of steatohepatitis[56,57]. Feeding an n-3
PUFA-enriched diet failed to prevent lipotoxic hepatocel-
lular injury and inflammatory recruitment, although acti-
vated PPAR alpha and suppressed hepatic de novo
lipogenesis. The researchers concluded: "Instead, the very
high levels of hepatic lipoperoxides may have abrogated
the protection that would otherwise be conferred by
PPAR alpha activation, and could also be responsible for
lipotoxic hepatocellular injury and inflammatory recruit-
ment."
Conclusions
Approximately 170 million people are infected worldwide
with HCV, making the condtion a major global health
problem. The combination of pegylated interferon (IFN)
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chronic HCV hepatitis, and long-term treatment has
been shown to improve the sustained virological
response (SVR) rate. However, the SVR rate still remains
at approximately 55% and patients with HCV genotype 1
infection combined with steatosis are significantly less
likely to achieve a week-12 early virological response
(EVR) or a sustained viro-logical response (SVR).
Nutrigenomics offer hope in the search for novel thera-
peutic and nutritional management options. Dietary FFA
composition can inhibit both HCV replication and HCV
induced- lipogenesic genes. Three nutrients, β-carotene,
vitamin D2, and linoleic acid are found to inhibit HCV
RNA replication and their combination to cause additive
and/or synergistic effects on HCV RNA replication.
PUFAs including AA, DHA and EPA are also demon-
strated to inhibit HCV RNA replication, while saturated
(lauric, myristic, and palmitic) and monounsaturated
(oleic) fatty acids induce HCV RNA replication.
PPAR and SREBP-1c gene, known to induce fatty acid
oxidation and synthesis respectively, are key targets for
PUFA control of hepatic gene expression. n-3 PUFAs are
weak agonists of PPARs compared with pharmacological
agonists, but has a significant effect on insulin sensitivity
in various tissues, particularly skeletal muscle. These
results provide useful information for improvement of
the SVR rates of patients receiving the currently standard
IFN therapy. In addition, these findings may contribute to
the development of nutritional supplements of use in the
treatment of people with chronic hepatitis C.
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